HOME / CONTACT US
繁體版 / 简体版
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate governance
    • Financials
    • 企業社會責任
    • 股東專區
    • 向股東報告
    • 財務資訊
    • Investor faqs
    • Corporate presentation
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
      • Governance Structure Shareholding Structure Board of Directors Audit Committee Compensation Committee Internal Audit Major Internal Policies
    • Financials
      • Financial Report / Financial Statements Stock Quotes
    • Investor FAQs
      • CONTACT US FAQs(category)
    • Corporate Presentation
      • Events and Presentations
    • 關於合一
      • History Team Collabration Nanchou Plant
    • SCIENCE
      • Pipeline & Therapeutic area ON101 OB318 FB825 FB704A FB918 SNS01 Technology
    • 人力資源
      • Careers Join us
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • CONTACT US
  • 繁體版
  • 简体版
 
Oneness announces on behalf of Cotton Field Organic Farm Inc., a major subsidiary, for a resolution by BODs on convening the 2021 Annual Shareholders' Meeting
2021-02-24
Oneness received the letter from MOHW informing that ON101 for DFUs has obtained the new drug approval and its drug certificate will be notified for receipt.
2021-02-24
Oneness submits an IND to US FDA on a phase II clinical trial on severe asthma of FB704A, a mAb developed from its own platform.
2021-02-15
Oneness will not proceed with the ON101 Phase3 clinical trial (ON101CLCT04) application with BfArM of Germany based on strategic consideration.
2021-02-09
Oneness Biotech Co.,LTD receives a U.S. patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on the developing new drug: ON101 Cream.
2021-02-02
Oneness Biotech Co.,LTD receives a European patent on antagonistic PDL1 aptamers.
2021-01-29

Copyright © Oneness Biotech Co., Ltd. All Rights Reserved.